CAPriCORN (Chicago Area Patient-Centered Outcomes Research Network) is a clinical data research network  consisting of research institutions, clinicians, patients and patient advocates. Funded by the Patient-Centered Outcomes Research Institute (PCORI) . 

 

Since 2014, MRAIA  has played a key role as neutral honest broker and data aggregator, serving as the data management hub, providing centralized infrastructure and technical support, and producing limited data analysis for multi-center research projects. Projects include but are not limited to:

 

COVID-19 Report: Summarizes numbers of COVID-19 patients and the distribution of their demographic characteristics.

Colorectal Cancer Care During the COVID-19 Pandemic: A retrospective data analysis study produces counts for conditions of interest and covariates of interest for the cohort during the study period.

irAED-CRG: Pilot project aims to develop and extend computational phenotypes to identify immune checkpoint inhibitor sensitive cancers in medical record data and assess the rate
of development of rare autoimmune complications of checkpoint inhibitor therapy.

 

BARIATRICS: An observational study examined benefits, complications, potential risks and other outcomes for 3 common types of bariatric surgeries.

 

ANTIBIOTICS: Study on childhood obesity to examine the relationship between antibiotic use in the first 2 years of life and in later childhood.  

HYPOGLYCEMIA: Assesses whether recurrent hypoglycemia is related to fragmentation of care, cardiovascular events, and mortality.

TRAUMA: Identifying clinical management of hemorrhage in trauma patients across non-trauma centers and trauma centers in Chicago.

NEXT-D (Natural Experiments for Translation in Diabetes) examined how the Affordable Care Act expansion of Medicaid affected diabetes diagnosis, treatment, and outcomes among the newly enrolled.​

 

NCI Next Generation Cohort: Investigated the history of invasive cancer between 2012-2017 for the identified population among the CAPriCORN health centers.

ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness): Compared the effectiveness of two daily doses of aspirin widely used to prevent heart attacks and strokes in individuals living with heart disease.